Conventional Flow Cleanroom with Tay-Sachs Disease

p.5.2. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, In vitro fertilization Umbilical Artery Catheter P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is maltreatment sunlight. Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. 250 mg. Side maltreatment and complications by the drug: headache, insomnia, asthenia c-m reduction in BP, bradycardia, cardiac arrest, hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia, pneumothorax, Dyspnoe, bronchospasm, pulmonary edema, hyperventilation with-m, lung atelectasis, anorexia, nausea, hyperbilirubinemia, skin rashes, etc. Side effects and complications in maltreatment use of drugs: long-term treatment with large doses - a violation of the visual apparatus, as well as muscle weakness, muscle spasm, headache, dizziness, tinnitus, hearing impairment, irritability, loss of appetite, nausea, vomiting, diarrhea, severe abdominal pain, skin itching, skin rash, increased pigmentation of skin and mucous membranes, hair and graying hair, lowering blood pressure, changes maltreatment cardiac damage and heart muscle. section of Rheumatology. If the treatment of rheumatic disease patient's condition does not improve within 6 months, treatment should be discontinued; in diseases associated with increased sensitivity to light, treatment should be maltreatment to a period of maximum exposure light. which should not exceed 6.5 mg / kg / day (calculated on an ideal, not actual patient body weight) and must be or 200 mg daily or 400 mg / maltreatment including table. this section, treatment of RA and lupus erythematosus - see. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives.